The u.v. difference spectra generated when methotrexate, trimethoprim or folate bind to Lactobacillus casei dihydrofolate reductase were analysed. The difference spectrum produced by methotrexate binding is shown to consist of three components: (a) one closely resembling that observed on protonation of methotrexate, reflecting an increased degree of protonation on binding; (b) a pH-independent contribution corresponding to a 40nm shift to longer wavelengths of a single absorption band of methotrexate; (c) a component arising from perturbation of tryptophan residue(s) of the enzyme. Quantitative analysis of the pH-dependence of component (a) shows that the pK of methotrexate is increased from 5.35 to 8.55 (±0.10) on binding. In contrast, folate is not protonated when bound to the enzyme at neutral pH. At pH 7.5, where methotrexate is bound 2000 times more tightly than folate, one-third of the difference in binding energy between the two compounds arises from the difference in charge state. A similar analysis of the difference spectra generated on trimethoprim binding demonstrates that this compound, too, shows an increase in pK on binding, but only from 7.22 to 7.90 (±0.10), suggesting that its 2,4-diaminopyrimidine ring does not bind to the enzyme in precisely the same way as the corresponding moiety of methotrexate.
The inhibition of dihydrofolate reductase (5,6,7,8-tetrahydrofolate-NADP+ oxidoreductase, EC 1.5.1.3) by 'anti-folate' drugs such as methotrexate and trimethoprim is of considerable therapeutic importance, but the molecular details of the interactions of these compounds with the enzyme remain incompletely understood. The substrates folate and dihydrofolate are 2-amino-4-oxopteridines, whereas all the most effective inhibitors have 2,4-diamino substituents on a pteridine, pyrimidine or related ring system (Hitchings & Burchall, 1965; Baker, 1967; Blakley, 1969; Roberts, 1977) . Changing the 4-oxo group to a 4-amino group leads to an increase in the affinity for the enzyme of as much as 10000-fold (Baker, 1967; Blakley, 1969) , and a number of proposals have been advanced to explain this dramatic effect.
In particular, Baker (1959 Baker ( , 1967 and Pullman (Perault & Pullman, 1961; Collin & Pullman, 1964) have drawn attention to the increased basicity of N-1 and of the 2-amino group in 2,4-diaminopteridines as compared with 2-amino-4-oxopteridines. Baker (1959 Baker ( , 1967 has suggested that the former compounds bind to the enzyme in the protonated (positively charged) form, and that an additional coulombic interaction is the basis of their substantially greater affinity for the enzyme. Some support Abbreviation used: Bistris, 2-[bis-(2-hydroxyethyl)-amino]-2-(hydroxymethyl)propane-1,3-diol.
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Vol. 171 for this proposal has come from studies of the u.v. difference spectra generated when methotrexate binds to dihydrofolate reductase from bacteriophage T4 (Erickson & Mathews, 1972) , Escherichia coli (Poe et al., 1974) or pig liver (Poe et al., 1975) , where a resemblance to the difference spectrum between neutral and protonated methotrexate was noted. We now report a detailed analysis of the difference spectra generated by the binding of methotrexate and trimethoprim to Lactobacillus casei dihydrofolate reductase, and a comparison of these spectra with those accompanying folate binding. This allows us to determine the ionization states of the bound ligands unambiguously, and to assess the contribution of protonation to the binding of the inhibitors. A preliminary report of part of this work has been presented (Hood & Roberts, 1977) .
Experimental Materials
Methotrexate was obtained from Nutritional Biochemicals Corp., Cleveland, OH, U.S.A., trimethoprim from Wellcome Research Laboratories, Beckenham, Kent, U.K., and folate and dihydrofolate were from Sigma (London) Chemical Co., Kingston upon Thames, Surrey, U.K. All other chemicals were of the highest purity commercially available and used without further purification.
Dihydrofolate reductase was purified from Lactobacillus casei MTX/R as described by Dann et al. (1976) .
Ligand concentrations were determined spectrophotometrically by using the following absorption coefficients: methotrexate, 6302 (pH 13)=22.0 x 103 litre molh' cm-' (Seeger et al., 1949) ; trimethoprim, 6271 (pH 1)=6.06 x 103 litre mol-' cm' (Roth & Strelitz, 1969) ; folate, 6282 (pH7)=27.6 x 103litre mol1' cm-' or 6365 (pH 13)=8.6x 103 litre molh' cm-' (Rabinowitz, 1960) . The enzyme concentration was determined from its A280 (6280= 27.2 x 103 litre molh1 cm-1; Dann et al., 1976) , by assaying its catalytic activity, and by fluorimetric titration with methotrexate (by procedures described by Dann et al., 1976) .
The buffers used were 100mM-KCl/50mM-Tris/ HCI (for pH7.0-8.5) and I00mM-KCl/50mM-Bistris/ HCI (for pH 5.3-7.0). All experiments were conducted at 25°C.
Optical absorption spectroscopy
Absorption spectra and difference spectra were measured with a Cary 118 spectrophotometer. All difference spectra were obtained by using matched quartz split-compartment cells with each compartment of path-length 0.4375cm. For each difference spectrum, a baseline was run first (sample and reference cells unmixed), then the difference spectrum (sample cell mixed), then a second baseline (sample and reference cells mixed). The two baselines differed by less than 0.002A unit, and their average was used to correct the difference spectrum. Enzyme concentrations of 10-20,uM (after mixing) were used, with a sufficient excess of ligand to ensure complete formation of the complex (except for folate at high pH, where the affinity was low; in this case the observed difference-spectra amplitudes were corrected for incomplete complex-formation by using the measured binding constant). Spectra were obtained over the range 250-450nm, with a bandwidth of 0.5-1.5nm and a scan rate of 0.2 or 0.5nm/s. For a compound that has different absorption characteristics in two ionization states, and whose pK changes on binding to an enzyme, the difference spectrum generated on binding will contain a component arising from the change in the degree of protonation of the ligand. The pH-dependence of the amplitude of this component of the difference spectrum is given by:
(8, go) [H+] ( Marquardt (1963) .
Determination ofbinding constants
Equilibrium constants for the binding of ligands to the enzyme were determined by measuring the quenching of the tryptophan fluorescence of the enzyme that accompanies complex-formation. The procedures used are described by Dann et al. (1976) and in more detail by Birdsall et al. (1978) . Enzyme concentrations of 0.02-5.0AM were used, and between 15 and 40 additions were made for each equilibriumconstant determination. The data were analysed by non-linear least-squares methods as outlined above, and the standard deviations quoted are those obtained from this analysis.
Results

Methotrexate
The binding of methotrexate (4-amino-4-deoxy-10-methylfolate) to L. casei dihydrofolate reductase produces a large-amplitude difference spectrum in the range 250-450nm (Fig. 1) . The main features are positive bands at 362 and 345 nm, and negative bands at 380, 320 and 260nm. Fig. 1 and folate have no effect on the spectrum in the wavelength region of interest and will be ignored. For simplicity, the designations 'neutral', 'protonated' and 'anionic' will be used for these compounds; these refer only to the charge state of the pteridine ring.) As noted for dihydrofolate reductase from other sources (Erickson & 'Mathews, 1972; Poe et al., 1974 Poe et al., , 1975 , there is some resemblance between the two spectra. Both spectra show large negative bands at approx. 380 and 260nm, but the 300-365nm region of the difference spectrum generated on binding to the enzyme is clearly more complex than that generated on protonation.
Perhaps the simplest interpretation of the difference spectrum associated with methotrexate binding to the enzyme would be that it is the sum of a protonation difference spectrum and other contribution(s) caused by the altered environment of methotrexate when bound to the enzyme. If there is a contribution to the spectrum from the protonation of methotrexate, then its amplitude should be pH-dependent (cf. eqn. 1). Fig. 2(a) shows the difference spectra generated on methotrexate binding to the enzyme at a series of pH values in the range 5.0-8.5 (limited by the stability of the enzyme). The difference spectra of Fig. 2(a) do not return completely to the baseline at 450nm; this is due to a weak long-wavelength n -÷ 7* band of methotrexate, which is red-shifted and somewhat increased in intensity when methotrexate binds to the enzyme. The form of the difference spectrum and the wavelengths of the band maxima do not change with pH in this range, but the amplitudes of the bands clearly do. This is most marked for the bands at 380 and 260nm, which correspond to features in the protonation difference spectrum. If this pH-dependence of the difference spectrum arises solely from the pH-dependence of the amplitude of the protonation contribution, the difference between the difference spectra obtained at two pH values should have the form of the protonation difference spectrum. In Fig. 2 (b) we compare the difference between the spectra at pH 5.3 and 7.3 with the protonation difference spectrum of free methotrexate. Clearly the two spectra are closely similar; in particular the wavelengths of the band maxima (260, 334 and 375 nm) are identical. The weak feature at 290-310nm in the enzyme difference spectrum reflects a pH-dependent contribution other than that from protonation of the methotrexate, most probably a perturbation of aromatic residue(s) of the protein, which differs slightly at the two pH values (see below).
This comparison shows clearly that there is a component in the difference spectrum generated on methotrexate binding to the enzyme that corresponds to the ligand's protonation difference spectrum, and Vol. 171 that thus reflects a greater degree of protonation (a higher pK) of methotrexate in its complex with dihydrofolate reductase than in free solution.
A quantitative estimate of the pK of methotrexate in the complex can now be obtained by fitting the amplitude of the difference spectrum as a function of pH to eqn. (1). The data for 400nm are shown in Fig. 3 , together with the best-fit curve from eqn. (1); the parameters used for this curve are given in the legend to Fig. 3 .
The absorption coefficient at this wavelength of protonated methotrexate appears to increase substantially on binding to the enzyme; however, this parameter is not well determined by the curve-fitting analysis, and if the data are analysed with the constraint that EB = cF, the value of pKB obtained changes by less than one standard deviation (±0.1 pH unit). The wavelength of 400nm was chosen for this analysis, since the only contribution to the difference spectrum at this wavelength is that from protonation Fig. 4 is a weaker negative band at 275nm. These latter peaks most probably arise from perturbation of one or more aromatic amino acid residues of the protein when the ligand binds, a third contribution to the total difference spectrum. Similar features are seen more clearly in the trimethoprim difference spectra (below).
Trimethoprim
The difference spectrum generated when trimethoprim [2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine] binds to dihydrofolate reductase at pH8.0 is compared with that caused by protonation of the ligand in Fig. 5 . In both cases there is a negative band at 292nm and a positive band at about 255nm; however, in the difference spectrum associated with binding to the enzyme the isosbestic point is at 266nm (rather than 275nm) and there is obvious fine structure on the 292nm band. As with methotrexate, it seems likely that this difference spectrum -.. is the sum of a contribution from protonation of the ligand and a contribution from other sources. The difference spectra generated on trimethoprim binding to the enzyme at various pH values in the range 5.3-8.2 are shown in Fig. 6(a) ; there is a marked pH-dependence of the amplitude of the difference spectrum, both at 292nm and at shorter wavelengths. The difference between the difference spectra obtained at pH5.3 and 8.0 is shown in Fig. 6(b) , where it is compared with the protonation difference spectrum. The agreement is excellent for the 292nm band, and reasonable at shorter wavelengths (see below), confirming the existence of a protonation component. Thus for trimethoprim, as for methotrexate, binding to the enzyme is associated with an increased degree of protonation of the ligand. The spectra in Fig. 6 show that for trimethoprim (unlike methotrexate) none of the bands in the difference spectrum can be said to arise solely from protonation. However, since the pK of trimethoprim is 7.22 in the free state, and apparently significantly higher in the bound state, at pH 5.3 both free and bound trimethoprim will be essentially fully protonated. The difference spectrum obtained at this pH (Fig. 6a) thus contains no protonation contribution. The two small positive bands at 289 and 296nm (responsible for the fine structure on the 292nm band at higher pH values) closely resemble those seen with methotrexate (see above) and most probably arise from perturbation of aromatic amino acid residues on ligand binding. In addition, there is a larger, negative, band at 268 nm, arising from perturbation of an absorption band of the ligand. The spectra in Fig. 6 show that the 289 and 296nm bands do not change significantly with pH, so that the pH-dependence of the amplitude of the protonation contribution to the 292nm band can be obtained by subtracting the AC292 at pH 5.3 from the corresponding values at higher pH.
By fitting this pH-dependence to eqn.
(1), we obtain an estimate for the pK of trimethoprim in the complex of 7.9 (±0.1), a difference of 0.68 unit from the value in free solution, indicating that protonated trimethoprim binds 4.8 (±1.1) times more tightly than the neutral molecule.
The pH-dependence of the amplitude of the difference spectrum at 268 nm is more complicated, and is not adequately described by eqn. (1). As noted above, there is a negative band at this wavelength that arises from sources other than protonation ofthe ligand, and it appears that the amplitude of this band decreases markedly as the pH is increased above about pH 8.0. This implies an additional pH-dependent change in the environment of the bound ligand at high pH, and this is also indicated by the pHdependence of the binding constant of trimethoprim. This is shown in the form of a Dixon (1953) plot in Fig. 7 , and the values measured at pH7.5 and 8.5 are included in Table 1 . The dotted curve in Fig. 7 shows the pH-dependence expected simply from the measured change in pK of the ligand on binding, and it is clear that ionization of a group or groups on the enzyme has the effect offurther decreasing the binding constant at pH values above 8.0.
Folate
For this 2-amino-4-oxopteridine there are two ionizations in the pH range of interest that affect the absorption spectrum: protonation (pK2.0) and anion formation (pK8.06).
The difference spectrum generated on folate binding to the enzyme at pH 5.3 is shown in Fig. 8 , along with the difference spectra between neutral folate and its protonated and anionic forms respectively. All three spectra show large negative bands in the region of 275nm, but at longer wavelengths there is very little resemblance between the spectrum produced by binding to the enzyme and either of the other spectra. In particular, although the change in ionization state of free folate leads to large bands in the difference spectrum at 356nm (As=-6 x I03litre molh I cm-1) for protonation or at 377nm (Ae=+4x103 litre mol-1 cm-') for anion formation, only a small band at 370nm (Ae=-9001itre molh1 cm-1) is seen 1978 + ,**.. when folate binds to the enzyme. The difference spectrum produced when folate binds to the enzyme is independent of pH over the range 5.3-8.5, in terms of both the wavelengths of the band maxima and their amplitudes. This shows clearly that over the whole of this pH range the ionic form of folate bound to the enzyme is the same as that of free folate. At pH7 and below, this is the neutral molecule. It is clear from the spectra in Fig. 8 that a pH-dependent contribution amounting to 10% of the protonation difference spectrum would be detectable. Since no such contribution is detectable at pH5.3, we can set an upper limit of 4.3 to the pK for protonation of folate in the complex. Above pH 7, the anionic form of folate becomes important; since the accessible pH range includes the pK of this ionization (8.06) and yet no component corresponding to the anion difference spectrum is discernible, it appears that the pK for this ionization is not significantly perturbed when folate binds to the enzyme.
The binding constants of folate at pH7.5 and 8.5 are given in Table 1 . Since the ionic form of the ligand does not change significantly on binding, the decrease in binding constant at the higher pH, which is less than that with trimethoprim, must be ascribed to the ionization of a group or groups on the enzyme.
Discussion
Methotrexate andfolate binding
There is clearly a general, though far from complete, resemblance between the difference spectrum generated by protonation of methotrexate and that observed when this inhibitor binds to L. casei dihydrofolate reductase. The quantitative analysis of the difference spectrum described here shows unambiguously that the pK of methotrexate is substantially increased when it binds to the enzyme, so that at pH 7.0, more than 97 % of the methotrexate bound to the enzyme is in the protonated form. In contrast, a similar analysis shows that folate is not protonated when bound to the enzyme at neutral pH. In addition, the pK for anion formation is not significantly perturbed on binding. Zakrzewski (1963) has proposed that folate and dihydrofolate bind to the enzyme as the enol tautomers (with a hydroxy group at the 4-position), whereas the keto form is known to be favoured in solution [see, e.g., Pfleiderer et al. (1960) and Brown & Jacobsen (1961) ]; this change in tautomeric form, if it occurs, should be reflected in the difference spectrum. As a model for the enol form of folate, we take 2-amino-4-methoxypteridine (Pfleiderer et al., 1960) ; in its neutral form, this molecule shows a strong absorption band at 358nm (e=65001itre molh' cm-'; Pfleiderer et al., 1960) . This is very similar to the long-wavelength absorption band of the anionic forms of 2-amino-4-Vol. 171 oxopteridine (360nm; e=70001itre mol-l cm-1; Pfleiderer et al., 1960) and folate (366nm, e= 72001itre mol-l cm-1; Rabinowitz, 1960) . The difference spectrum between the enol and keto tautomers ought therefore to resemble that between the anionic and neutral forms. There is no indication of such a component in the difference spectrum generated when folate binds to the enzyme. We conclude that bound folate is in the normal keto tautomeric form, and at pH 7.0 is more than 90% in the neutral ionization state.
The substrate and inhibitor are thus shown to be in different ionization states when bound to the enzyme at neutral pH, as first postulated by Baker (1959, 1967) . We can now assess quantitatively the contribution that this difference makes to the large difference in binding constant between methotrexate and folate. The measured pK values of methotrexate in the free and bound states show that the protonated form binds 1600 (±300) times more tightly to the enzyme than does the neutral form, a Gibbs freeenergy difference of 18.18 (±0.84)kJ/mol. This must presumably be due to an interaction with a negatively charged carboxylate group on the enzyme. Both 2,4-diamino-and 2-amino-4-oxopteridines are protonated on N-1, with the formation of an amidinium structure involving N-1, C-2 and the 2-amino group (Pfleiderer et al., 1960; Dieffenbacher & von Philipsborn, 1969; Konrad & Pfleiderer, 1970; Ewers et al., 1973 Ewers et al., , 1974 . Such a structure would be able to form two hydrogen bonds as well as a charge-charge interaction with a carboxylate group. The recently reported crystal structure of the E. coli dihydrofolate reductase-methotrexate complex (Matthews et al., 1977) shows that the carboxylate group of Asp-27 is indeed in close proximity to N-1 of bound metho- (see, e.g., Blakley, 1969) . Table 2 shows that protonated methotrexate binds very tightly to the enzyme: a binding constant of 2.7 x 1010M-1 corresponds to a Gibbs free-energy change of -59.36kJ/mol. Furthermore, even the neutral form of methotrexate binds 170 times more tightly (12.5kJ/mol) to the enzyme than does folate. This shows clearly that the protonation of methotrexate, although it contributes substantially to the overall binding energy, cannot be solely responsible for the increased affinity of methotrexate compared with folate. In fact, of the 18.8kJ/ mol difference in binding energy between folate and methotrexate at pH7.5, two-thirds arise from the Feeney et al., 1977; Roberts, 1977; Roberts et al., 1977 The difference spectra generated on methotrexate binding to dihydrofolate reductase from bacteriophage T4, E. coli and pig liver (Erickson & Mathews, 1972; Poe et al., 1974 Poe et al., , 1975 are similar to that observed with the L. casei enzyme. The maxima occur at the same wavelengths, and the amplitudes of the bands at 260 and 380nm, which arise predominantly from the protonation contribution, are very similar, indicating that the degree of protonation of the bound methotrexate is similar in each case. The major difference in the spectra observed with the enzyme from different sources is in the amplitude of the negative band at 320nm. Jaffe & Orchin, 1962) . This suggests that a more specific interaction with the enzyme may be involved, but the absorption spectrum of methotrexate is not yet sufficiently well understood for us to suggest any particular model. In contrast with the difference spectra generated by methotrexate binding, those observed when folate binds to the enzymes from L. casei, bacteriophage T4 (Erickson & Mathews, 1972 ) and E. coli (Poe et al., 1974) are markedly different. Although folate is a substrate for all these enzymes, its activity relative to dihydrofolate does vary markedly from one enzyme to another.
Trimethoprim binding
Like methotrexate, trimethoprim binds preferentially to the enzyme in the protonated form, but in this case the preference amounts only to a factor of 4.8 (3.8 kJ/mol). 2,4-Diaminopyrimidines are protonated on.N-1 (Brown & Teitei, 1965) , and it is generally assumed that the diaminopyrimidine ring of trimethoprim and related compounds binds to the enzyme in the same site as that occupied by the corresponding part of the pteridine ring of methotrexate. The effects of trimethoprim on the histidine and tyrosine resonances in the n.m.r. spectrum of L. casei dihydrofolate reductase are very similar to, though not identical with, those of methotrexate Feeney et al., 1977) . However, the much smaller effect of protonation on trimethoprim binding than on methotrexate binding implies a significantly different interaction with the negatively charged carboxylate group on the enzyme in the two cases. The trimethoxybenzyl moiety of trimethoprim makes a major contribution to its binding energy: at pH6.5 the binding constant for trimethoprim is 2.6 x 107 M-1, whereas that for 2,4-diaminopyrimidine is 1.28 x 103M-1 (Birdsall et al., 1978) . It is possible that optimal interaction of the trimethoxybenzyl group with the enzyme requires a somewhat different orientation of the trimethoprim molecule in the binding site from that for optimal interaction with the carboxylate group. In this connection it is interesting that the band at 260nm in the trimethoprim difference spectrum, which arises from sources other than protonation, is clearly pH-dependent above pH8, in contrast with the 'non-protonation' contribution to the methotrexate spectrum, which is independent of pH. Although the origin of this difference is unknown, it does further imply a difference in the interactions of pyrimidines and pteridines with the enzyme.
Both methotrexate and trimethoprim appear to perturb the spectrum of one or more aromatic amino acid residues in the protein when they bind. The wavelength maxima in the trimethoprim difference spectrum, where they can be measured fairly precisely, are 289 and 296nm. The solvent perturbation difference spectrum of tryptophan has bands at 284 and 294nm, whereas that of tyrosine has bands at 278 and 287nm (Herskovits, 1967) . It seems likely therefore that a tryptophan residue is perturbed when these ligands bind. 19F n.m.r. studies of 6-fluorotryptophan-labelled enzyme show that methotrexate binding causes a substantial shift in the resonance position of a single tryptophan residue. Treatment of dihydrofolate reductase from E. coli or L. casei with N-bromosuccinimide leads to complete loss of activity concomitant with the oxidation of a single tryptophan residue (Liu & Dunlap, 1974; Williams, 1975; Freisheim et al., 1977 ; K. Hood & G. C. K. Roberts, unpublished work), whereas with the enzyme from Streptococcus faecium, the loss of activity correlates with modification of two tryptophan residues (Warwick et al., 1972) .
